Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05272709 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TT-702 in Patients With Advanced Solid Tumours.

Study acronym: CURATE
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 9 months later Jun 2027 → Apr 2028
Primary endpoints removed 7 → 4 primary endpoints
Enrollment reduced 68% 188 → 60 participants
See other at-risk trials from Cancer Research UK

Record History

  1. Primary and study completion pushed from Jun 2027 to Apr 2028 Primary endpoint(s) modified · Enrollment reduced: 188 → 60 participants · Trial arms changed: 6 → 4 · 4 morev4 Show 7 more changesShow less
    • Primary endpoint(s) modified
    • Enrollment reduced: 188 → 60 participants
    • Trial arms changed: 6 → 4
    • Interventions: Darolutamide (Drug), TT-702 (Drug) to Anti-PD-1 and PD-L1 agent (Drug), TT-702 (Drug)
    • Eligibility criteria shortened, about 281 words
    • Secondary endpoints: 15 to 16
    • Study description shortened, about 8 words

    See this version in full on ClinicalTrials.gov ↗

  2. Enrollment target: 114 to 188 Primary and study completion dates: Sep 2025 to Jun 2027 · Primary endpoints: 5 to 7 · Interventions: TT-702 (Drug) to Darolutamide (Drug), TT-702 (Drug) · 5 morev3 Show 8 more changesShow less
    • Primary and study completion dates: Sep 2025 to Jun 2027
    • Primary endpoints: 5 to 7
    • Interventions: TT-702 (Drug) to Darolutamide (Drug), TT-702 (Drug)
    • Eligibility criteria expanded, about 769 words
    • Secondary endpoints: 11 to 15
    • Study description expanded, about 44 words
    • Site contacts updated at 1 of 3 sites
    • Study arms: 4 to 6

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 2 to 3v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This clinical trial is evaluating the drug candidate TT-702 in patients with advanced solid tumours. The main aims of the trial are to determine the maximum dose of TT-702 that can be given safely to patients alone and in combination with other anti-cancer agents.
Trial Details
NCT Number NCT05272709
Lead Sponsor Cancer Research UK
Collaborators: Teon Therapeutics, Inc.
Conditions Advanced Solid Tumors
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov